Nexstim Oyj: New Study Presents Impressive Results of Nexstim SmartFocus nTMS Language Mapping New Study Presents Impressive Results of Nexstim SmartFocus nTMS Language Mapping Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that a new study published in Cancers in January presents impressive results of nTMS language mapping in a large amount of patients. Using the robustness of Nexstim SmartFocus nTMS data, the authors also introduce a new and more precise classification of what it means to be a "language eloquent" tumour, challenging the traditional methods that seek to only identify hemispheric dominance for language. The study "Non-Invasive Mapping for Effective Preoperative Guidance to Approach Highly Language-Eloquent Gliomas-A Large Scale Comparative Cohort Study Using a New Classification for Language Eloquence", using Nexstim's NBS System with SmartFocus nTMS, was published by a neurosurgical team at Technical University of Munich (TUM) in Germany.